-$0.92 Earnings Per Share Expected for Tempest Therapeutics, Inc. (NASDAQ:TPST) This Quarter

Brokerages predict that Tempest Therapeutics, Inc. (NASDAQ:TPSTGet Rating) will announce ($0.92) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Tempest Therapeutics’ earnings. The highest EPS estimate is ($0.85) and the lowest is ($0.98). Tempest Therapeutics reported earnings of ($7.63) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 87.9%. The firm is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Tempest Therapeutics will report full-year earnings of ($3.92) per share for the current fiscal year, with EPS estimates ranging from ($3.99) to ($3.80). For the next fiscal year, analysts anticipate that the firm will post earnings of ($4.16) per share, with EPS estimates ranging from ($4.52) to ($3.76). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Tempest Therapeutics.

Several equities analysts recently issued reports on the company. Piper Sandler decreased their price target on Tempest Therapeutics from $20.00 to $10.00 in a report on Friday, May 13th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Tempest Therapeutics in a report on Friday. Finally, Zacks Investment Research upgraded Tempest Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Friday.

In related news, Director Thomas Woiwode bought 2,118,644 shares of Tempest Therapeutics stock in a transaction on Friday, April 29th. The shares were purchased at an average price of $2.36 per share, for a total transaction of $4,999,999.84. Following the completion of the acquisition, the director now owns 2,118,644 shares in the company, valued at $4,999,999.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 3.30% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in TPST. Morgan Stanley raised its position in Tempest Therapeutics by 174.0% in the 3rd quarter. Morgan Stanley now owns 1,989 shares of the company’s stock valued at $29,000 after buying an additional 1,263 shares during the last quarter. Geode Capital Management LLC raised its position in Tempest Therapeutics by 47.4% in the 4th quarter. Geode Capital Management LLC now owns 34,346 shares of the company’s stock valued at $181,000 after buying an additional 11,045 shares during the last quarter. Franklin Resources Inc. acquired a new stake in Tempest Therapeutics in the 3rd quarter valued at approximately $221,000. Renaissance Technologies LLC raised its position in Tempest Therapeutics by 47.9% in the 4th quarter. Renaissance Technologies LLC now owns 50,430 shares of the company’s stock valued at $266,000 after buying an additional 16,326 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in Tempest Therapeutics in the 3rd quarter valued at approximately $421,000. Institutional investors and hedge funds own 34.92% of the company’s stock.

Tempest Therapeutics stock traded up $0.02 during mid-day trading on Tuesday, hitting $2.85. The stock had a trading volume of 19 shares, compared to its average volume of 210,008. The stock has a 50-day simple moving average of $3.29 and a two-hundred day simple moving average of $4.57. Tempest Therapeutics has a 12 month low of $2.16 and a 12 month high of $41.00. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.01 and a quick ratio of 3.01.

About Tempest Therapeutics (Get Rating)

Tempest Therapeutics Inc, a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors.

Further Reading

Get a free copy of the Zacks research report on Tempest Therapeutics (TPST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tempest Therapeutics (NASDAQ:TPST)

Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.